Abstract: 【Abstract】 Central retinal vein occlusion (CRVO) is a common, sight-threatening retinal vascular disorders. The etiology of CRVO is complicated and current treatments for CRVO and its sequelae such as macular edema are still tough. However, there are many emerging treatments in recently years. Intravitreal pharmacologic agents which include anti-vascular endothelial growth factor (Bevacizumab, Ranibizumab, Pegaptanib, and VEGF Trap-Eye), triamcinolone acetonide and sustained delivery corticosteroid device (fluocinolone acetonide and dexamethasone) are promising. There are also some researches on the efficiency of laser and surgery. Several large, well-designed, prospective, randomized controlled trials are still ongoing worldwidely. Although the efficiency and safety of some treatments have been proved by evidence-based medicine, there are still lots of questions which should be answered on the way from clinical trial to clinical practice. (Ophthalmol CHN, 2012, 21: 222-227)

Key words:  central retinal vein occlusion, macular edema/therapy, clinical trial, evidence-based medicine